---

BENIGN PROSTATIC ENLARGEMENT (BPE / BPH)

Complete Urology Resident Teaching Guide

---

CHAPTER 1: DEFINITIONS & TERMINOLOGY

Q: What is the difference between BPH, BPE, and LUTS? Why does it matter?

Examiner tip: Always say "BPH is a histological diagnosis." Size ≠ symptoms. A 150 g prostate may cause no obstruction; a 30 g prostate may cause severe BOO.

---

CHAPTER 2: EPIDEMIOLOGY

Q: Give me prevalence figures for BPH.

• Histologic prevalence at autopsy (classic figures - must memorize):
  • Age 31-40 years: 8%
  • Age 41-50 years: ~20%
  • Age 51-60 years: ~50%
  • Age 61-70 years: ~65%
  • Age 71-80 years: ~80%
  • Age >80 years: ~90%
• At age 55: ~25% of men report obstructive voiding symptoms
• At age 75: ~50% of men complain of decreased force and caliber of stream

Q: What are the risk factors for BPH?

1. Age - most important; BPH is rare before 40
2. Functioning testes - castrated men do NOT develop BPH (classical observation)
3. Genetics - ~50% of men who need surgery before age 60 have a heritable form
   • Autosomal dominant inheritance
   • First-degree male relatives: 4-fold increased risk
4. Race - higher incidence in African Americans; lower in Asians
5. Diet - high fat, red meat associated; soy (phytoestrogens) may be protective
6. Obesity / metabolic syndrome - associated
7. Estrogen levels of aging - increased estrogen sensitizes prostate to testosterone

Q: What two conditions are REQUIRED for BPH to develop?

Answer: Aging + functioning testes (intact androgen production)

Eunuchs castrated before puberty NEVER develop BPH - a fundamental principle.

---

CHAPTER 3: ANATOMY - THE ZONES OF THE PROSTATE

Q: In which zone does BPH develop? Where does prostate cancer develop?

McNeal Zone Anatomy (must know perfectly):

• BPH arises in the transition zone around the periurethral glands
• The enlarged transition zone compresses the peripheral zone - creating the "surgical capsule"
• This surgical capsule is what makes simple prostatectomy (enucleation) possible

Q: What is the surgical capsule of the prostate?

The compressed rim of peripheral zone tissue surrounding the hyperplastic transition zone. This natural cleavage plane allows enucleation in open simple prostatectomy (Millin's / Freyer's procedure).

---

CHAPTER 4: PATHOPHYSIOLOGY

Q: Explain the molecular basis of BPH.

A. Endocrine/Androgen Role:

1. Testosterone is converted to Dihydrotestosterone (DHT) by 5-alpha reductase type 2 in prostatic stromal cells
2. DHT is the primary intraprostatic androgen - 10x more potent than testosterone in stimulating prostate growth
3. DHT binds androgen receptors → stimulates epithelial and stromal cell proliferation
4. Castration → DHT falls → prostate involutes (this is the basis of 5-ARI treatment)

B. Estrogen Role:

• Aging men have increased estrogen:testosterone ratio
• Estrogen upregulates androgen receptors in prostatic stroma → sensitizes prostate to free testosterone
• Estrogens acting through stromal and epithelial estrogen receptors may contribute to prostatic disease

C. Stromal-Epithelial Interaction:

• BPH involves both stromal (smooth muscle, collagen) and epithelial elements
• Stromal predominance → responds to alpha-blockers
• Epithelial predominance → responds to 5-ARIs
• Composition varies → explains variable treatment response

D. Growth Factors:

• FGF (Fibroblast Growth Factor) - promotes stromal growth
• KGF (Keratinocyte Growth Factor) - stromal to epithelial signaling
• IGF-1 (Insulin-like Growth Factor)
• EGF (Epidermal Growth Factor)
• TGF-beta - inhibitory; may be reduced in BPH

E. Two Mechanisms of Urinary Obstruction in BPH:

This is why alpha-blockers work immediately (relaxing dynamic tone) while 5-ARIs take months (need epithelial cell apoptosis to reduce static component).

---

CHAPTER 5: PATHOLOGY

Q: Describe the gross and microscopic pathology of BPH.

Gross:

• Normal prostate weight: 20 g
• BPH weight: typically 20-100 g, can exceed 200 g
• Cut surface: rubbery nodular tissue with pale yellow-white areas of stromal overgrowth and small cystic spaces (glandular dilation)
• Lateral lobes enlarge most; median lobe when enlarged projects into bladder (ball-valve obstruction - no lobe palpable on DRE!)

Microscopic:

• Nodular growth pattern - hallmark
• Nodules contain: smooth muscle + collagen stroma and/or hyperplastic epithelial glands
• Epithelial lining: pseudostratified tall columnar cells with basal cells
• Corpora amylacea (prostatic concretions) may be seen
• No cytologic atypia, no invasion

Q: What is the clinical importance of the median lobe?

The median lobe projects into the bladder neck, causing obstruction despite a small palpable prostate on DRE. It can cause ball-valve type obstruction. It is NOT palpable rectally. Treatment: TURP or HoLEP.

Bladder Changes due to BPH (secondary effects):

1. Detrusor hypertrophy - trabeculation (raised ridges = trabeculae)
2. Cellules - small outpouchings between trabeculae
3. Diverticula - larger outpouchings that extend beyond bladder wall (have no muscle → do not empty → stone formation, infection, even carcinoma)
4. Chronic urinary retention → hydronephrosis → obstructive uropathy → renal failure

---

CHAPTER 6: SYMPTOMS - LUTS CLASSIFICATION

Q: Classify LUTS. Give examples of each type.

Storage (Irritative) Symptoms - due to detrusor overactivity / reduced bladder compliance:

• Frequency
• Urgency
• Urgency incontinence
• Nocturia
• Mnemonic: FUN + Nocturia (Frequency, Urgency, Nocturia)

Voiding (Obstructive) Symptoms - due to BOO:

• Hesitancy (difficulty initiating)
• Weak/poor stream
• Straining/pushing
• Intermittency
• Prolonged voiding
• Terminal dribbling

Post-Micturition Symptoms:

• Incomplete emptying sensation
• Post-micturition dribble

Key point: Irritative symptoms are often MORE bothersome to patients. Storage symptoms correlate poorly with degree of obstruction. Nocturia is the most common complaint and worst for quality of life.

---

CHAPTER 7: IPSS (INTERNATIONAL PROSTATE SYMPTOM SCORE)

Q: What is the IPSS? How many questions? What are the cutoffs?

IPSS = AUA Symptom Score (identical questionnaire)

• 7 symptom questions (each scored 0-5) + 1 Quality of Life question (scored 0-6)
• Total symptom score: 0-35

The 7 Questions (Mnemonic: "I-FIF-W-S-N" or FUWISE + Nocturia):

1. Incomplete emptying - sensation of not emptying completely
2. Frequency - urinate again <2 hours after last void
3. Intermittency - stop and start
4. Urgency - difficulty postponing urination
5. Weak stream
6. Straining - push/strain to begin urination
7. Nocturia - times up at night (scored 0-5)

Score Interpretation:

QoL Question:

Examiner Q: IPSS is a symptom score - what does it NOT tell you?

It does NOT tell you if the cause is BPH. It does NOT quantify bladder function. It does NOT predict surgical outcome. It assesses symptom burden and QoL.

---

CHAPTER 8: DIAGNOSIS

Q: A 65-year-old man presents with LUTS. What is your initial evaluation?

Mandatory Initial Evaluation (Recommended by AUA/EAU):

1. History
   • Duration, severity of LUTS
   • Medication history (diuretics, anticholinergics, sympathomimetics)
   • Prior urologic history (stricture, surgery, radiation)
   • Sexual function (baseline before treatment)
   • Fluid intake habits
2. IPSS Score
3. Physical Examination
   • DRE - prostate size (normal = walnut-sized ~20 g), consistency (smooth, rubbery = BPH; hard/nodular = cancer), tenderness
   • Suprapubic palpation (distended bladder)
   • Focused neurological exam
4. Urinalysis - rule out infection, hematuria, glucose
   • If hematuria → further evaluation (cystoscopy, upper tract imaging)
5. PSA (in appropriate candidates)
   • Adds information about prostate size (PSA correlates with volume)
   • Predicts likelihood of BPH progression
   • Rules out concurrent prostate cancer
6. Post-Void Residual (PVR) - by ultrasound
   • Normal: <50 mL
   • Mildly elevated: 50-200 mL (may not need immediate action)
   • Significantly elevated: >200-300 mL → suggests detrusor decompensation

Optional / Indicated Studies:

Q: What is Qmax and what value suggests BOO?

• Qmax = maximum urinary flow rate (normal >15 mL/s)
• Qmax <10 mL/s = strongly suggestive of BOO
• Qmax 10-15 mL/s = equivocal
• Must void >150 mL for a valid reading

---

CHAPTER 9: INDICATIONS FOR TREATMENT

Q: When do you MUST treat (absolute indications) vs. when is treatment elective?

Absolute Indications for Surgical Treatment:

1. Acute urinary retention (AUR) - failed trial without catheter (TWOC)
2. Chronic urinary retention with overflow incontinence
3. Recurrent urinary tract infections secondary to BPH
4. Recurrent gross hematuria due to BPH (after ruling out malignancy)
5. Bladder stones secondary to BPH/BOO
6. Renal insufficiency/obstructive uropathy from BPH
7. Large bladder diverticula secondary to BPH

Mnemonic: RRRASH - Retention, Renal impairment, Recurrent UTI, Recurrent hematuria, Azotemia (renal impairment), Stones, Hematuria

Elective/Relative Indications:

• Moderate-severe LUTS (IPSS 8+) not responding to medical therapy
• Patient preference
• Significant QoL impact

---

CHAPTER 10: MANAGEMENT

Treatment Algorithm:

IPSS 0-7 (Mild) → Watchful Waiting
IPSS 8-19 (Moderate) → Medical Therapy (first-line)
IPSS 20-35 (Severe) / Failed medical therapy / Absolute indications → Surgery

---

A. WATCHFUL WAITING (Active Surveillance)

• For mild symptoms (IPSS ≤7) or moderate symptoms with minimal bother
• Lifestyle modifications:
  • Reduce fluid intake in evenings
  • Avoid caffeine and alcohol (bladder irritants)
  • Bladder retraining (timed voiding)
  • Treat constipation
  • Avoid drugs that worsen symptoms (antihistamines, decongestants)
• Reassess annually

---

B. MEDICAL THERAPY

1. Alpha-1 Adrenergic Blockers (Alpha-Blockers)

Q: Mechanism of alpha-blockers in BPH?

Block alpha-1 receptors in prostatic smooth muscle, bladder neck, and proximal urethra → reduce dynamic component of obstruction → improve urine flow within days to weeks

• Orthostatic hypotension (worst with non-selective)
• Floppy Iris Syndrome (IFIS) - CRITICAL: inform ophthalmologist before cataract surgery, especially with tamsulosin
• Retrograde ejaculation (most with silodosin ~28%)
• Dizziness, fatigue, nasal congestion

Q: What is IFIS and why is it important?

Intraoperative Floppy Iris Syndrome - tamsulosin causes alpha-1A blockade in iris dilator muscle → iris floppiness during cataract surgery → pupil constriction, iris prolapse, complications. Must inform ophthalmologist. Stopping tamsulosin before surgery does NOT reliably prevent it (effect persists months). Ophthalmologist uses modified surgical technique.

---

2. 5-Alpha Reductase Inhibitors (5-ARIs)

Q: Mechanism of 5-ARIs?

Block conversion of testosterone to DHT → reduce intraprostatic DHT → epithelial apoptosis → prostate volume reduction by 20-30% over 6-12 months

• Prostate volume >30-40 g (or PSA >1.5 ng/mL)
• Reduce risk of AUR and need for surgery (PLESS trial: finasteride reduced AUR by 57%, surgery by 55%)

• Decreased libido (~6%)
• Erectile dysfunction (~5%)
• Decreased ejaculatory volume
• Gynecomastia (~1%)
• PSA halved - remember: 5-ARIs reduce PSA by ~50% after 6 months; must double PSA to get true PSA equivalent

Q: A patient on finasteride has PSA of 2.5 ng/mL. What is his "true" PSA?

Multiply by 2 = 5 ng/mL equivalent. Failure of PSA to fall by 50% on 5-ARI should raise suspicion for prostate cancer.

---

3. Combination Therapy

• Best for men with moderate-severe LUTS + large prostate (>30 g) + high risk of progression
• MTOPS trial (Medical Therapy of Prostatic Symptoms): doxazosin + finasteride reduced clinical progression by 67% vs. monotherapy
• CombAT trial: dutasteride + tamsulosin superior to either alone for symptom improvement and reducing risk of AUR/surgery in men with prostate >30 g

---

4. Antimuscarinic / Anticholinergic Agents

• For storage/OAB symptoms (urgency, frequency, nocturia) predominant
• Tolterodine, Oxybutynin, Solifenacin, Darifenacin, Fesoterodine
• Caution: May precipitate urinary retention (use only when PVR <200 mL and Qmax >5 mL/s)
• Can be combined with alpha-blocker safely

---

5. Beta-3 Agonists

• Mirabegron - beta-3 agonist → bladder relaxation → storage symptom improvement
• Advantage over antimuscarinics: no dry mouth, less risk of urinary retention
• Can be used when antimuscarinics are contraindicated (glaucoma, constipation)

---

6. PDE-5 Inhibitors

• Tadalafil 5 mg daily - FDA approved for LUTS/BPH
• Mechanism: smooth muscle relaxation in prostate, bladder neck, urethra via cGMP
• Benefit: treats both LUTS and erectile dysfunction simultaneously
• Does NOT improve Qmax significantly

---

7. Phytotherapy (Plant Extracts)

• Serenoa repens (Saw palmetto), Pygeum africanum, beta-sitosterol
• Evidence is weak; NOT recommended by AUA/EAU guidelines as primary therapy
• May have mild symptomatic benefit in some trials

---

C. SURGICAL TREATMENT

Q: What is the GOLD STANDARD surgical treatment for BPH?

TURP (Transurethral Resection of the Prostate) - remains the gold standard benchmark against which all other procedures are compared.

---

1. TURP (Transurethral Resection of the Prostate)

• Prostate 20-80 g (most effective range)
• Failed medical therapy
• Absolute surgical indications (AUR, recurrent UTI, stones, renal impairment, hematuria)

• Monopolar TURP: uses glycine 1.5% or sorbitol/mannitol irrigation (non-conducting, hypotonic) - risk of TURP syndrome
• Bipolar TURP: uses normal saline irrigation - NO TURP syndrome - now preferred

Q: What is TURP syndrome? How do you prevent and treat it?

• Absorption of hypotonic irrigation fluid (glycine) through open venous sinuses
• Results in: hyponatremia, dilutional hyponatremia, hypervolemia, hypo-osmolarity
• Presentation: nausea, visual disturbances (glycine metabolite = ammonia), confusion, seizures, cardiovascular collapse
• Classically occurs when resection >1 hour and venous sinuses widely opened
• Prevention: limit resection time to <1 hour; bipolar TURP uses saline → eliminates syndrome
• Treatment: slow sodium correction, diuretics (furosemide), ICU monitoring; hypertonic saline if severe seizures

Q: What is the most common complication of TURP?

Retrograde ejaculation (~90%) - semen goes into bladder instead of being expelled antegrade due to disruption of bladder neck sphincter mechanism. This is NOT erectile dysfunction. Must be counseled pre-operatively.

---

2. Open Simple Prostatectomy (Enucleation)

• Very large prostate (>80-100 g) - when TURP too lengthy/risky
• Bladder stones, bladder diverticula requiring simultaneous repair
• Hip deformity precluding lithotomy position

---

3. Holmium Laser Enucleation of Prostate (HoLEP)

• Most effective endoscopic technique for any prostate size
• Holmium:YAG laser enucleates entire transition zone (similar to open enucleation but endoscopic)
• Advantages: size-independent (can treat even 200+ g prostates), minimal bleeding (suitable for anticoagulated patients), short catheter time, day-case procedure
• Disadvantage: steep learning curve (~50-100 cases)
• EAU guidelines: HoLEP is now recommended as alternative to TURP for ALL prostate sizes
• Requires morcellator to remove enucleated tissue

---

4. Laser Vaporization Techniques

---

5. Minimally Invasive Surgical Therapies (MIST)

---

6. Comparison Table: Surgical Options

---

CHAPTER 11: ACUTE URINARY RETENTION (AUR)

Q: A 70-year-old man presents with inability to void for 8 hours with lower abdominal pain and a palpable bladder. Management?

Definition:

Immediate Management:

1. Urethral catheterization (14-16 Fr) - immediate relief
2. If urethral catheterization fails → suprapubic catheterization
3. Drain bladder slowly (controversial: some drain all at once, some clamp at 500 mL - evidence does not support slow drainage to prevent hematuria)
4. Send urine for culture
5. Check serum creatinine (rule out acute obstructive uropathy)
6. Start alpha-blocker (tamsulosin) immediately

TWOC (Trial Without Catheter):

• Remove catheter after 24-72 hours on alpha-blocker
• Success rate: ~50-70% (better in first-time AUR with identifiable precipitant)
• Precipitated AUR (e.g., after surgery, anesthesia, overdistension) → higher success TWOC
• Spontaneous AUR → lower success

Predictors of Failed TWOC:

• Voided volume >1 liter at catheterization
• Large prostate (>30 g)
• Detrusor pressure <35 cmH₂O on urodynamics
• Prolonged retention (>7 days)
• Elderly with poor detrusor function

Failed TWOC → definitive surgical treatment (TURP)

---

CHAPTER 12: CHRONIC URINARY RETENTION (CUR)

Low-Pressure CUR:

• PVR >300 mL, no upper tract dilation, normal renal function
• Patient often not in distress
• May present with overflow incontinence

High-Pressure CUR:

• Raised intravesical pressure transmitted to upper tracts
• Bilateral hydronephrosis, bilateral hydroureter
• Impaired renal function (obstructive nephropathy)
• This is an absolute indication for immediate catheterization and surgery

Q: Post-obstructive diuresis - what is it and how do you manage it?

After relieving chronic high-pressure retention, kidneys excrete retained sodium, water, and urea → large volumes of dilute urine

• Monitor urine output hourly
• Replace 50-75% of urine output IV to avoid dehydration and electrolyte imbalance
• Monitor Na, K, urea, creatinine 6-hourly
• Usually self-limiting; pathological diuresis if >200 mL/hr persisting

---

CHAPTER 13: PSA IN BPH

Q: What is the role of PSA in BPH evaluation?

1. Predicts prostate volume: PSA 1.5-4 ng/mL → likely large prostate; supports 5-ARI use
2. Predicts risk of progression: PSA >1.5 ng/mL = high risk of AUR or surgery
3. Rules out concurrent prostate cancer (but overlap in PSA values)
4. 5-ARIs reduce PSA by 50% - must adjust interpretation
5. PSA density = PSA/prostate volume; >0.15 ng/mL/mL suggests cancer over BPH

PSA Ranges and BPH:

• Elevated PSA in BPH is due to: increased volume of PSA-producing epithelium, loss of basement membrane integrity, microinfarcts
• BPH PSA rarely >10 ng/mL (higher values → suspect cancer)

---

CHAPTER 14: DIFFERENTIAL DIAGNOSIS OF LUTS

Q: BPH is not the only cause of LUTS. What else causes similar symptoms?

---

CHAPTER 15: HIGH-YIELD EXAM QUESTIONS & MNEMONICS

Must-Know High-Yield Facts:

---

MNEMONICS:

• Detrusor decompensation / Diverticula (large)
• Infections (recurrent UTIs)
• Hematuria (recurrent)
• Evacuation failure (AUR - retention)
• Failure of kidneys (renal impairment)
• Stones (bladder stones)

• Frequency, Intermittency, Force (weak stream), Waiting (hesitancy), Straining, Nocturia + Incomplete emptying

• 5-ARIs = Shrink (size reduction, long-term, large prostates)
• Alpha-blockers = Smooth (smooth muscle relaxation, rapid relief)

---

CHAPTER 16: EXAMINER TRAPS & COMMON MISTAKES

1. "BPH is benign prostatic HYPERtrophy"

WRONG. It is HYPERplasia - increase in cell NUMBER. Hypertrophy = increase in cell SIZE. BPH is a histological diagnosis of hyperplasia.

2. "A large prostate always causes more obstruction"

WRONG. Size does NOT correlate with symptoms or degree of obstruction. A 200 g prostate may have mild LUTS; a 30 g prostate can cause severe BOO. Dynamic tone matters more.

3. "Stop tamsulosin before cataract surgery"

NOT sufficient. IFIS can persist for months after stopping. The ophthalmologist must be informed so they can modify technique. The key intervention is telling the surgeon, not stopping the drug.

4. "Correct hyponatremia rapidly in TURP syndrome"

WRONG. Rapid correction causes central pontine myelinolysis. Correct slowly (max 8-10 mEq/L per 24 hours).

5. "TURP cures erectile dysfunction"

WRONG. TURP causes ED in ~3-5%. It does NOT treat pre-existing ED.

6. "PSA is always elevated in BPH"

Not always. Normal PSA with large prostate does not exclude cancer. But PSA >10 in BPH alone is unusual.

7. "5-ARIs can be used immediately in AUR"

5-ARIs take 6-12 months to work; alpha-blockers are used for AUR/TWOC.

---

CHAPTER 17: CLINICAL VIGNETTES (EXAM-STYLE PRACTICE)

• Diagnosis: Moderate-severe BPH with BOO
• Treatment: Combination alpha-blocker + finasteride/dutasteride (large prostate, risk of progression); if fails → TURP

• IFIS risk - must inform ophthalmic surgeon. Modified surgical technique needed (iris hooks, Malyugin ring, OVD). Stopping tamsulosin does not reliably prevent IFIS.

• High-pressure CUR/AUR causing renal impairment → Absolute surgical indication
• Catheterize immediately; monitor for post-obstructive diuresis; optimize renal function; plan TURP once stable

• Retrograde ejaculation (90% incidence post-TURP)
• Semen goes back into bladder. Post-coital urinalysis/centrifuge shows sperm.
• If fertility desired: sympathomimetics (pseudoephedrine), sperm retrieval from post-ejaculatory urine, assisted reproduction

• TURP syndrome - stop procedure, secure airway, slow IV sodium correction, furosemide, ICU; if seizures → hypertonic saline (3%) cautiously

---

---

---

BLADDER MASS / BLADDER CANCER

Complete Urology Resident Teaching Guide - Examiner Level

---

CHAPTER 1: OVERVIEW & TERMINOLOGY

Q: What do we mean by "bladder mass"? Classify it.

Classification of Bladder Masses:

• Urothelial (Transitional Cell) Carcinoma - >90% of all bladder tumors
• Squamous Cell Carcinoma (SCC) - 1-7%
• Adenocarcinoma - 2%

• Leiomyoma (most common benign bladder tumor)
• Pheochromocytoma (paraganglioma)
• Lymphoma
• Sarcoma (rhabdomyosarcoma - in children)
• Carcinoid

• Direct invasion: colorectal cancer, prostate cancer, cervical cancer
• Hematogenous: melanoma, breast, lymphoma

Examiner tip: When you say "bladder tumor" in clinical context = urothelial carcinoma until proven otherwise. Squamous and adeno are context-specific (think SCC = schistosomiasis; Adeno = urachal/exstrophy).

---

CHAPTER 2: EPIDEMIOLOGY

Q: Give me the epidemiology of bladder cancer.

• 4th most common cancer in men (after prostate, lung, colorectal)
• 9th most common in women
• Male:Female ratio = 3-4:1
• Peak incidence: 6th-7th decade
• 540,000 cases worldwide; 188,000 deaths per year (2015 data)
• 70% are Non-Muscle-Invasive (NMIBC) at presentation; 30% are Muscle-Invasive (MIBC)
• 5-year survival: NMIBC ~85-90%; MIBC ~50-60%; Metastatic ~5-15%

---

CHAPTER 3: RISK FACTORS & ETIOLOGY

Q: What are the risk factors for bladder cancer? Give occupational carcinogens.

Risk Factors (Mnemonic: "SOAP-DR"):

Occupational Carcinogens - KEY INDUSTRIES:

• Tanner (leather)
• Rubber industry
• Paint and dye workers
• Gas and tar workers
• Hairdressers
• Plumbers and painters

Q: What is the latent period for occupational bladder cancer?

Up to 20-30 years between exposure and tumor development. This is why industrial bladder cancer appears in 6th-7th decade despite exposure in 20s-30s.

Q: Why does cyclophosphamide cause bladder cancer?

Acrolein - a urinary metabolite of cyclophosphamide - is directly toxic to urothelium. Prevention: Mesna (2-mercaptoethanesulfonate sodium) which binds and inactivates acrolein in the urine. Vigorous hydration also used.

---

CHAPTER 4: ANATOMY OF THE BLADDER

Q: Describe the bladder wall layers from inside out - why does this matter for staging?

Bladder Wall Layers (Inside to Outside):

1. Urothelium (transitional epithelium) - 3-7 cell layers thick; umbrella cells on surface
2. Lamina propria (subepithelial connective tissue) - contains muscularis mucosae (thin, discontinuous)
3. Muscularis propria (detrusor muscle) - three interlocking smooth muscle layers (inner longitudinal, middle circular, outer longitudinal)
4. Perivesical fat (peritoneum covers dome only)

Critical staging distinction: T1 tumors invade lamina propria (NON-muscle-invasive); T2 tumors invade muscularis propria (MUSCLE-INVASIVE). This is the single most important distinction in bladder cancer management.

Muscularis Mucosae Trap:

• The lamina propria contains a thin, discontinuous smooth muscle layer called muscularis mucosae
• Examiner trap: Pathologists must distinguish muscularis mucosae from muscularis propria
• Invasion of muscularis mucosae = still T1 (NMIBC)
• Invasion of muscularis propria = T2 (MIBC)
• If pathology report says "muscle present but uncertain which layer" → repeat TURBT

---

CHAPTER 5: PATHOLOGY

Q: Describe the pathology of urothelial carcinoma - gross and microscopic.

Histological Types:

Gross Morphology of Urothelial Carcinoma:

Microscopic (WHO 2004 Grading):

• PUNLMP - Papillary Urothelial Neoplasm of Low Malignant Potential (low risk of recurrence, very low progression risk)
• Low-grade urothelial carcinoma
• High-grade urothelial carcinoma

Old WHO 1973 grading (still used in many centers):

• G1 = Well differentiated
• G2 = Moderately differentiated
• G3 = Poorly differentiated

Q: What is CIS and why is it important?

Carcinoma in situ (CIS/Tis) is a flat, high-grade, non-papillary urothelial carcinoma confined to the urothelium. Key features:

• Appears as a flat, erythematous (red velvet) patch
• Easily missed on white light cystoscopy - best detected by blue light / PDD (hexaminolevulinate) or NBI
• Always high grade by definition
• Can be primary (isolated CIS), secondary (concurrent with papillary tumor), or concurrent (both)
• High risk of progression to muscle-invasive disease (~50% if untreated)
• First-line treatment: intravesical BCG (not TURBT alone - cannot resect flat lesion meaningfully)
• CIS in prostatic urethra or upper tract = contraindication to orthotopic neobladder

---

CHAPTER 6: STAGING

Q: Give me the TNM staging of bladder cancer. What is the most important stage boundary?

T Stage (Primary Tumor):

Tis  = Carcinoma in situ (flat, high-grade, non-invasive)
Ta   = Non-invasive papillary carcinoma (confined to urothelium)
T1   = Invades lamina propria (subepithelial connective tissue)
─────────────────────────── CRITICAL BOUNDARY ───────────────────────────
T2a  = Invades superficial muscularis propria (inner half)
T2b  = Invades deep muscularis propria (outer half)
T3a  = Microscopic perivesical invasion
T3b  = Macroscopic perivesical invasion (extravesical mass)
T4a  = Invades prostate stroma, seminal vesicles, uterus, vagina
T4b  = Invades pelvic wall or abdominal wall (FIXED tumor)

N Stage:

• N0 = No nodal disease
• N1 = Single node ≤2 cm in true pelvis
• N2 = Single node 2-5 cm OR multiple nodes ≤5 cm in true pelvis
• N3 = Any node >5 cm

M Stage:

• M0 = No distant metastasis
• M1a = Distant lymph nodes beyond common iliac
• M1b = Other distant metastases (lung, liver, bone most common)

Stage Grouping:

---

CHAPTER 7: CLINICAL PRESENTATION

Q: A 65-year-old man presents with painless hematuria. What is your differential and how do you approach it?

Classic Presentation:

• Painless gross hematuria - 85% of bladder cancer patients; most common presentation
• "Painless" distinguishes it from stones (painful) and infection (dysuria)
• ALWAYS investigate - a single episode of painless hematuria must be evaluated
• Rule of thumb: hematuria = bladder cancer until proven otherwise

Other Presentations:

• Storage LUTS (frequency, urgency, dysuria) - especially in CIS
• Recurrent UTI
• Flank pain (ureteric obstruction by tumor at UVJ)
• Bone pain, weight loss, leg edema - advanced/metastatic disease
• Incidental finding on ultrasound

Q: Why does CIS cause storage LUTS (irritative symptoms) even though it's non-invasive?

CIS is biologically aggressive - it releases inflammatory mediators, disrupts the urothelial barrier, and directly irritates the detrusor muscle despite not invading it. This is why irritative symptoms + negative infection cultures → CIS must be excluded.

Hematuria Workup Algorithm:

Painless Hematuria
↓
Urine culture (rule out UTI) → if positive, treat, but STILL investigate if recurs
Urine cytology
Flexible cystoscopy (gold standard for bladder)
CT Urogram (upper tract + bladder evaluation)
↓
If any abnormality → rigid cystoscopy + TURBT under GA

---

CHAPTER 8: INVESTIGATIONS

Q: How do you investigate a patient with suspected bladder cancer?

1. Urine Tests:

• Urinalysis - confirm hematuria (macro or micro)
• Urine culture - exclude infection
• Urine cytology - exfoliated urothelial cells examined:
  • Sensitivity: LOW for low-grade (30-50%); HIGH for high-grade and CIS (80-90%)
  • Specificity: very high (~99%)
  • Positive cytology with negative cystoscopy = always suspect CIS in upper tracts or prostatic urethra
  • Morning void is best specimen

2. Cystoscopy:

• Flexible cystoscopy under LA - outpatient, gold standard for diagnosis
• Describes: number of tumors, size, location, papillary vs. sessile, CIS (red patches)
• Bimanual examination under anaesthesia (EUA) - crucial before and after TURBT:
  • Palpable mass before TURBT = at least T3
  • Mass that becomes mobile after TURBT = T3
  • Fixed mass after TURBT = T4b
  • Mass disappears after TURBT = T2 or less

Enhanced Cystoscopy:

3. Imaging:

4. Urine Biomarkers:

• NMP-22 (Nuclear Matrix Protein), BTA stat, FISH (UroVysion) - detect chromosomal aneuploidy
• None has surpassed cystoscopy in accuracy - not routinely recommended in guidelines
• FISH useful when cytology equivocal

---

CHAPTER 9: NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC) - MANAGEMENT

Q: How do you manage NMIBC? Walk me through it step by step.

Step 1: TURBT (Transurethral Resection of Bladder Tumor)

• Rigid cystoscope under general or spinal anaesthesia
• Bimanual EUA before and after resection
• Resection must include base of tumor + deep muscle (detrusor) to accurately stage
• For large tumors: fractionated resection (piece by piece)
• For small (<3 cm) solitary tumors: en bloc resection may reduce implantation recurrence
• Must document: number of tumors, size, papillary/nodular/sessile features, concern for CIS
• Separate biopsies from tumor base and surrounding urothelium if CIS suspected
• Mapping biopsies: trigone, dome, right/left/anterior/posterior walls - if CIS suspected

Step 2: Immediate Post-TURBT Intravesical Chemotherapy

• Single dose of Mitomycin C (MMC) within 6 hours of TURBT
• Reduces recurrence by 12% (meta-analysis level evidence)
• Kills floating tumor cells before they implant
• Contraindications: suspected bladder perforation (intraperitoneal or extraperitoneal), complete resection uncertain
• Do NOT give if perforation suspected (extravasation of MMC is dangerous)

Step 3: Risk Stratification

This is a critical exam topic - memorize the risk categories

AUA/EAU Risk Stratification (NMIBC):

Step 4: Adjuvant Treatment Based on Risk

Low Risk → Surveillance alone (after single MMC dose)

• Cystoscopy at 3 months, then annually for 5 years

Intermediate Risk → Intravesical Chemotherapy (MMC)

• 6-week induction course (weekly x6)
• Consider 1-year maintenance
• Reduces recurrence; minimal effect on progression

High Risk → Intravesical BCG Immunotherapy

Q: How does BCG work in bladder cancer?

BCG (Bacillus Calmette-Guérin) is a live attenuated strain of Mycobacterium bovis. It is instilled into the bladder where it binds to fibronectin on the urothelial surface → taken up by macrophages and urothelial cells → triggers TH1 immune response → local cytokine storm (IL-2, IL-12, TNF, IFN-gamma) → kills tumor cells and induces tumor-specific T-cell immunity.

• Induction: Weekly x 6 instillations
• Maintenance: 3-weekly instillations at 3, 6, 12, 18, 24, 30, 36 months (full 3-year course)
• Full 3-year maintenance reduces progression by ~37% compared to induction alone

• Traumatic catheterization (defer 2 weeks)
• Gross hematuria (defer)
• Active UTI (treat first)
• Immunosuppressed patients (HIV, transplant, on steroids)
• Within 2 weeks of TURBT

Q: BCG-failure - what is it and what do you do?

BCG Failure Categories:

• Pembrolizumab (checkpoint inhibitor, PD-1 antibody) - FDA approved
• Nadofaragene firadenovec (intravesical gene therapy)

Step 5: Re-TURBT (Second Look TURBT)

1. High-grade T1 tumor (mandatory)
2. Large/multifocal T1 tumor
3. No muscle in initial specimen
4. Incomplete resection

---

CHAPTER 10: MUSCLE-INVASIVE BLADDER CANCER (MIBC) - MANAGEMENT

Q: A patient has T2 bladder cancer on TURBT. What is the standard treatment?

Standard: Neoadjuvant Chemotherapy + Radical Cystectomy

A. Neoadjuvant Chemotherapy (NAC)

• Regimens: GC (Gemcitabine + Cisplatin) or M-VAC (Methotrexate, Vinblastine, Adriamycin, Cisplatin)
• Benefit: Improves overall survival by 5-7% (absolute); meta-analysis confirmed
• Mechanism: Treats micrometastatic disease before surgery; can downstage tumor
• Must be cisplatin-eligible: GFR >60, ECOG ≤2, no hearing loss/neuropathy
• 3 cycles GC or 3-4 cycles M-VAC before surgery
• pT0 (complete pathological response) in 20-40% → excellent prognosis

Examiner Q: Why neoadjuvant rather than adjuvant?

Patients tolerate chemo better before surgery (bowel intact, better nutritional status, better renal function). Earlier treatment of micrometastases. Higher completion rate. Studies consistently show neoadjuvant benefit; adjuvant data weaker.

B. Radical Cystectomy

• Standard: External iliac, internal iliac, obturator nodes (up to common iliac bifurcation)
• Extended: Also includes common iliac and presacral nodes
• Therapeutic and staging benefit; minimum 10-16 nodes needed

1. Lower midline incision (umbilicus to pubic symphysis)
2. Assess liver and retroperitoneum for metastases
3. Bilateral pelvic lymphadenectomy (external iliac, internal iliac, obturator fossa)
4. Ligate lateral pedicles (superior and inferior vesical vessels)
5. Divide ureters
6. Divide posterior ligaments posterior to Denonvilliers' fascia
7. Divide endopelvic fascia and puboprostatic ligaments
8. Divide dorsal venous complex (DVC)
9. Divide and mobilize urethra
10. Remove bladder + prostate en bloc
11. Urinary diversion (ileal conduit standard)

Q: Can you spare nerves during cystectomy?

Nerve-sparing (NVB preservation) is possible in selected patients (organ-confined disease, no CIS near bladder neck). Preserves erectile function in 40-60%. Contraindicated if: positive surgical margin risk, CIS at bladder neck/prostatic urethra.

C. Urinary Diversion Options

1. Ileal Conduit (Bricker) - STANDARD

• Most common urinary diversion; lowest complication rate
• 15 cm segment of ileum; ureters implanted (Bricker = separately; Wallace = as single plate)
• Creates incontinent stoma in right iliac fossa
• External appliance worn
• Complications:
  • Ureteroileal leak/stricture (5%)
  • Stomal complications - stenosis, parastomal hernia (20%)
  • Upper tract dilatation (30%)
  • Recurrent UTI
  • Metabolic: hyperchloremic metabolic acidosis (ileum absorbs Cl⁻ and excretes HCO₃⁻)

2. Orthotopic Neobladder (Studer Pouch - most common)

• 57 cm of detubularised ileum fashioned into a low-pressure spherical pouch
• Anastomosed directly to urethra
• Proximal "chimney" for ureteric implantation (antireflux)
• Patient voids by relaxing pelvic floor + Valsalva
• 15-30% require CISC (clean intermittent self-catheterization) to empty fully
• Best for: highly motivated patients with good renal/liver function

• CIS involving prostatic urethra (anastomotic recurrence risk)
• Tumor at bladder neck/urethra
• Poor renal function (creatinine >150 umol/L)
• Inflammatory bowel disease
• Prior pelvic radiotherapy (relative)
• Inability to self-catheterize
• Female: tumor at bladder neck (must resect urethra)

3. Continent Cutaneous Diversion (Heterotopic)

• Pouch (ileum/colon) + continent catheterizable channel to skin (appendix = Mitrofanoff; ileum = Yang-Monti)
• Stoma at umbilicus or right iliac fossa
• Patient catheterizes through channel every 4-6 hours
• For those needing urethrectomy but wanting continent diversion

4. Ureterosigmoidostomy (Mainz II / Sigma Pouch)

• Ureters implanted into sigmoid colon; patient defecates urine + feces
• No external appliance needed - popular in developing countries
• Requires intact anal sphincter
• Risks: Ascending pyelonephritis, hyperchloremic hypokalemic metabolic acidosis (colonic absorption of urinary chloride), adenocarcinoma at anastomosis (due to mixing urine + feces), bowel frequency
• Limited use in modern urology

Diversion Comparison:

Q: What is the metabolic complication of each bowel segment used for diversion?

• Ileum/Colon: Absorbs Cl⁻, secretes HCO₃⁻ → Hyperchloremic metabolic acidosis (most common with colon > ileum)
• Stomach: Secretes Cl⁻/H⁺, absorbs HCO₃⁻ → Hypochloremic hypokalemic metabolic alkalosis
• Jejunum (avoid!): Secretes Na⁺ and Cl⁻ → severe hyponatremia, hyperkalemia, metabolic acidosis (jejunal conduit syndrome)

---

CHAPTER 11: BLADDER-PRESERVING THERAPY (TRIMODALITY)

Q: Is radical cystectomy the only option for MIBC?

Trimodality Therapy (TMT) = Bladder-Sparing Protocol

1. Maximal TURBT (debulk tumor as much as possible)
2. Concurrent chemoradiotherapy (cisplatin-based chemo as radiosensitizer + external beam RT 64-66 Gy)
3. Cystoscopic reassessment at mid-treatment; salvage cystectomy if incomplete response

• ~80% of responders keep their native bladder long-term

• Solitary T2 tumor
• No hydronephrosis
• Complete or near-complete TURBT possible
• Good bladder function
• No CIS
• Fit for both chemo and RT

• Multifocal MIBC
• Associated CIS
• Hydronephrosis
• Poor bladder function
• Bilateral hip replacements (RT field)
• Inflammatory bowel disease (RT complication risk)

---

CHAPTER 12: METASTATIC BLADDER CANCER

Q: How do you treat metastatic bladder cancer?

First-Line:

• Cisplatin-eligible: GC (Gemcitabine + Cisplatin) or M-VAC - ORR 40-60%; median OS ~14 months
• Cisplatin-ineligible: Carboplatin + Gemcitabine OR Atezolizumab/Pembrolizumab (PD-L1+ tumors)

Second-Line:

• Pembrolizumab (anti-PD-1) - FDA approved; ORR ~21%
• Atezolizumab, Durvalumab, Avelumab (anti-PD-L1)
• Erdafitinib - FGFR3 inhibitor (FGFR3 mutation/fusion present in ~25% of bladder cancers)
• Enfortumab vedotin - antibody-drug conjugate targeting Nectin-4; excellent response rates

Enfortumab Vedotin + Pembrolizumab (EV-302 trial):

• Now first-line for metastatic bladder cancer (regardless of cisplatin eligibility)
• Dramatically improved OS vs. platinum chemotherapy
• Represents a paradigm shift (2023-2024 data)

---

CHAPTER 13: UPPER TRACT UROTHELIAL CARCINOMA (UTUC)

Q: How does upper tract urothelial carcinoma differ from bladder cancer?

• UTUC = urothelial carcinoma of renal pelvis + ureter
• Accounts for 5-10% of all urothelial carcinomas
• Renal pelvis: ureter ratio = 2:1
• Field effect/field change: urothelium from renal calyx to urethra has same embryological origin → "condemned mucosa" theory → 30-50% of UTUC patients develop bladder cancer; 1-4% of bladder cancer patients develop UTUC
• Lynch syndrome (HNPCC): highest risk of UTUC - must take family history
• Diagnosis: CTU + ureteroscopy + selective ureteral cytology

• Standard: Nephroureterectomy + bladder cuff excision (remove entire ureter to avoid ureteral stump recurrence)
• Imperative kidney cases / bilateral: segmental ureterectomy, endoscopic treatment
• UTUC patients need lifelong cystoscopic surveillance for bladder cancer

---

CHAPTER 14: SURVEILLANCE AFTER BLADDER CANCER TREATMENT

Q: How do you follow up patients after treatment for bladder cancer?

After TURBT (NMIBC):

• Upper tract imaging (CTU) every 1-2 years for high-risk NMIBC

After Radical Cystectomy (MIBC):

• CT chest/abdomen/pelvis every 3-6 months for 2 years, then annually
• Urethral wash cytology (if urethra retained) every 6 months → annual
• Metabolic monitoring (creatinine, electrolytes, Vit B12 if ileum used)

---

CHAPTER 15: HIGH-YIELD FACTS & MNEMONICS

Must-Know Table:

---

MNEMONICS:

• Smoking, Occupational amines, Arsenic, Phenacetin/Pelvic XRT, Drugs (cyclophosphamide), Recurrent inflammation

• Any T1 = high risk
• Any CIS = high risk
• Any High Grade = high risk
• Multiple/large/recurrent Ta = intermediate to high

• Stomach = Alkalosis
• Jejunum = Worst (hypoNa, hyperK, acidosis) - NEVER USE
• Ileum/Colon = Hyperchloremic Acidosis

• Fever, Dysuria, Sepsis (BCG), Granulomatous complications

---

CHAPTER 16: EXAMINER TRAPS & COMMON MISTAKES

1. "I'll give the mitomycin C 24 hours after TURBT"

WRONG. Must be within 6 hours (ideally in recovery room). After 6 hours, cells have already implanted. Timing is critical.

2. "Re-TURBT is optional for T1 tumors"

WRONG. Re-TURBT at 2-6 weeks is mandatory for high-grade T1. Upstaging in up to 40%. Missing this is a clinical governance failure.

3. "BCG is the treatment for all NMIBC"

WRONG. BCG is for high-risk NMIBC. Low-risk gets surveillance ± single MMC. Intermediate gets intravesical MMC course. Over-using BCG exposes patients to unnecessary toxicity.

4. "BCG sepsis - treat with ciprofloxacin alone"

WRONG. BCG is a mycobacterium - use isoniazid + rifampicin + corticosteroids. Standard antibiotics do not cover it.

5. "Imaging after TURBT is better for T staging"

WRONG. Perivesical edema after TURBT gives false T3 staging on CT/MRI. Always image BEFORE TURBT.

6. "A small prostate means no MIBC"

WRONG. Tumor T stage is unrelated to prostate size. T4a means the tumor has invaded the prostate stroma - confirm with biopsies and imaging.

7. "Positive cytology but normal cystoscopy = no cancer"

WRONG. Positive cytology + negative cystoscopy = CIS until proven otherwise (or upper tract urothelial cancer). Must perform: blue-light cystoscopy, mapping biopsies, retrograde pyelography + ureteroscopy.

8. "Female cystectomy is easier - no prostate"

WRONG. Female radical cystectomy = anterior pelvic exenteration including uterus, ovaries, anterior vaginal wall. Women must be counseled about loss of uterine and ovarian function. More difficult pelvic dissection in obese females.

9. "Patient declined cystectomy for T2 - so no other option"

WRONG. Offer Trimodality Therapy (TMT) - maximal TURBT + concurrent chemoradiotherapy. Similar 5-year survival in selected patients, preserving the bladder.

---

CHAPTER 17: CLINICAL VIGNETTES

• Full hematuria workup: urine cytology + CT urogram + flexible cystoscopy
• Even one episode = mandatory investigation
• If cystoscopy shows papillary tumor → TURBT + EUA

1. Re-TURBT at 2-6 weeks (upstaging to T2 in up to 40%)
2. If still T1HG → intravesical BCG (6-week induction + maintenance x3 years)
3. Counsel about radical cystectomy option (especially if multifocal, recurrent, or with CIS)

• BCG-refractory disease = disease at 6 months despite adequate BCG
• Standard recommendation: Radical cystectomy
• If unfit/declines: pembrolizumab, nadofaragene, clinical trial

• Neoadjuvant GC chemotherapy x3 cycles followed by radical cystoprostatectomy + ileal conduit (or neobladder if urethra clear + motivated patient)
• Discuss nerve-sparing if organ-confined

• Hyperchloremic metabolic acidosis (non-anion gap)
• From ileal segment absorbing chloride and excreting bicarbonate
• Treatment: oral sodium bicarbonate supplementation

1. Blue-light (PDD) cystoscopy with hexaminolevulinate + mapping biopsies
2. If still negative bladder → bilateral retrograde pyelograms + ureteroscopy to exclude upper tract TCC
3. Cannot ignore positive cytology with "normal" white-light cystoscopy

---

---

---

PERCUTANEOUS NEPHROSTOMY (PCN)

Complete Urology Resident Teaching Guide - Examiner Level

---

CHAPTER 1: WHAT IS PCN?

Q: Define Percutaneous Nephrostomy (PCN).

• It is one of the most commonly performed urologic interventional procedures
• Technical success rate: 98-99% in dilated systems; 85-96% in non-dilated systems
• Can be performed by urologist OR interventional radiologist
• Bedside US-guided PCN is a core urologist skill

---

CHAPTER 2: ANATOMY - THE FOUNDATION OF SAFE PCN

Q: Why is knowledge of renal anatomy essential before performing PCN? Where is the ideal entry point?

Renal Orientation in Retroperitoneum:

• Upper poles lie more posterior than lower poles (due to oblique axis)
• Right kidney: adjacent to 12th rib, liver, duodenum, hepatic flexure; 2-3 cm lower than left (liver pushes it down)
• Left kidney: adjacent to 11th and 12th ribs, pancreas, spleen, splenic flexure

Vascular Anatomy - THE KEY TO SAFE ACCESS:

• Anterior division - supplies anterior 2/3 of kidney (4 segmental branches)
• Posterior division - supplies posterior 1/3 (1 segmental branch)

Entry through a POSTERIOR CALYX naturally traverses Brödel's line → minimal vascular injury risk

Posterior vs. Anterior Calyces - Must Know:

The Pleura:

• Pleura attaches at level of 11th rib - important for supracostal access planning
• Punctures above 12th rib (supracostal) risk pneumothorax, hemothorax, hydrothorax
• Always account for respiratory movement when targeting calyx

---

CHAPTER 3: INDICATIONS FOR PCN

Q: Give me the complete list of indications for PCN.

Indications (Mnemonic: "OUPAUF"):

Most Common Clinical Scenarios Requiring PCN:

1. Obstructed infected kidney (stone + infection = emergency)
2. Bilateral ureteric obstruction from pelvic malignancy
3. Solitary kidney obstruction
4. Pre-PCNL access planning
5. Post-operative ureteric injury (leaks, ligation)

Most urgent indication: PYONEPHROSIS - infected obstructed kidney. This patient can deteriorate to septic shock within hours. Do NOT delay PCN, even at night.

---

CHAPTER 4: CONTRAINDICATIONS

Q: Are there absolute contraindications to PCN?

Relative Contraindications:

Examiner trap: "Can you do PCN in a coagulopathic patient?"

Yes - coagulopathy is a relative, not absolute contraindication. In pyonephrosis with septic shock, the risk of death from NOT doing PCN exceeds the bleeding risk. Correct coagulopathy simultaneously and proceed.

---

CHAPTER 5: PRE-PROCEDURE PREPARATION

Q: How do you prepare a patient for PCN?

Pre-Procedure Checklist:

1. Informed consent - written, with discussion of risks (listed in Table 85.3)
2. IV access - large bore cannula
3. IV fluids - adequate hydration (helps kidney function + contrasts safety)
4. Bloods:
   • Full blood count
   • Coagulation (INR <1.3, platelets >80,000/dL)
   • Renal function (U&E, creatinine)
   • Serum electrolytes (correct acidosis, hyperkalemia before procedure)
5. Urine culture - take before procedure; guide antibiotic choice
6. Antibiotic prophylaxis:
   • Low risk: single dose broad-spectrum IV (e.g., gentamicin + amoxicillin OR cephalosporin)
   • High risk (elderly, diabetic, indwelling catheter, bacteriuria, ureteroenteric conduit): continue and modify based on cultures
7. Review all imaging - CT, IVU, ultrasound - assess anatomy, position of colon, spleen, liver
8. Mark side - confirm side with imaging and patient
9. Anaesthetic:
   • Standard: monitored sedoanalgesia (IV opioids + midazolam) + local anaesthetic infiltrated to renal capsule
   • Restless/confused patient: general anaesthesia (safer for both patient and operator)
   • Paediatric: general anaesthesia mandatory

Coagulation Targets (must memorize):

• INR < 1.3
• Platelets > 80,000/dL
• APTT < 1.5x normal
• Stop aspirin 7 days before elective PCN; stop clopidogrel 5 days before
• Warfarin: bridge to INR correction with LMWH

---

CHAPTER 6: TECHNIQUE OF PCN - STEP BY STEP

Q: Describe the technique of PCN in detail.

Patient Positioning:

• Standard: Prone or prone-oblique position (brings posterior calyces end-on for puncture)
• Prone-oblique (ipsilateral side elevated ~20-30°): widens intercostal spaces, moves colon anteriorly
• True lateral or supine/oblique: increases risk to liver, spleen, bowel - more technically demanding
• CT guidance / alternative positions for: horseshoe kidney, pelvic kidney, retrorenal colon

IMAGE: Single Puncture PCN Technique

The Seldinger Technique (standard method):

• Choose posterior calyx (preferably lower or middle pole for simple drainage)
• Upper pole calyx: better for accessing PUJ/ureter; higher risk of pleural injury
• On US: posterior calyces = most superficial, medial, with less dense urine (non-dependent)
• On fluoroscopy: posterior calyces = least densely opacified in prone position; maximum movement on 30° oblique swings

• Use 18-22G needle
• Approach: align needle with calyx "like a dart at a dartboard" - aim for the calyx centre end-on
• Advance needle during expiration (kidney moves least)
• Aspirate urine to confirm intracalyceal position
• If clear urine: inject small volume of contrast (~10 mL) to confirm position - AVOID OVERDISTENSION
• If infected urine (turbid/pus): do NOT inject contrast - risk of bacteremia; proceed directly

• 0.035-inch Amplatz stiff guidewire passed through needle into collecting system
• Aim to coil wire in renal pelvis OR pass down ureter (for stability)
• Confirm position under fluoroscopy

• Maintain wire position
• Nick skin with scalpel blade at entry point

• Serial fascial dilators over wire to dilate subcutaneous tissue and renal parenchyma
• For simple PCN: dilate to 8-10 French
• For PCNL access: dilate to 28-30 French (Amplatz dilators or balloon dilator)

• Standard PCN catheter: 8-12 French pigtail catheter
• Advance over wire into collecting system
• Pull string to form pigtail loop within renal pelvis (self-retaining mechanism)
• Confirm drainage of urine/aspirate

• "Roman sandal" suture technique (wrap suture around tube going away from and back toward skin)
• Drain-fix dressing applied on top
• Catheter connected to drainage bag

IMAGE: Fluoroscopically-guided PCNL access sequence

---

CHAPTER 7: GUIDANCE MODALITIES - WHICH ONE, WHEN?

Q: Compare ultrasound vs. fluoroscopy vs. CT guidance for PCN. What are the advantages of each?

Three Guidance Methods:

No guidance method has been proven superior to another. Choice depends on local expertise, resources, and whether the system is dilated.

Key Fluoroscopy Trick - Identifying Posterior Calyces:

• Inject gas (CO₂ or air, max 20 mL slowly) into collecting system
• Gas = buoyant → fills non-dependent posterior calyces in prone position
• Clearly highlights posterior calyces as dark gas-filled structures
• Caution: Avoid gas extravasation (risk of air embolism or gas in retroperitoneum)

• Calyces showing the largest arc of movement when rotating C-arm from +30° to -30° oblique = most posterior calyces

---

CHAPTER 8: SINGLE vs. DOUBLE PUNCTURE TECHNIQUE

Q: When do you need a second puncture for PCN?

Single Puncture PCN:

• Direct puncture into target posterior calyx
• Guidewire advanced; tract dilated; catheter placed
• Standard technique for most PCNs

Double Puncture PCN:

• First puncture enters infundibulum or renal pelvis (suboptimal position)
• OR first puncture is into anterior calyx
• A second puncture is then performed into the appropriate posterior calyx under pyelographic guidance

• Entry into infundibulum → second puncture into calyx
• Entry into renal pelvis → second puncture (direct calyceal entry needed for PCNL)

---

CHAPTER 9: SPECIAL SITUATIONS

Q: How does PCN differ in: non-dilated kidney, horseshoe kidney, transplant kidney, pregnancy, and children?

1. Non-Dilated Kidney (technically challenging)

• Calyces not visible on US
• Success rate: 85-96% (vs. 98-99% in dilated systems)
• Technique:
  • Use double contrast pyelography (gas + contrast)
  • IV contrast to opacify system if needed
  • Puncture with 22-G needle; minimal contrast injection
  • Wire and catheter placed as quickly as possible (system can decompress on needle entry)
• A non-dilated system may still need PCN (e.g., urosepsis from encrusted stent, non-dilating obstruction)

2. Horseshoe Kidney

• Anatomical disposition: lies lower, isthmus connects lower poles anteriorly, calyces and pelves are more anteriorly oriented
• Higher risk from normal posterior approach
• Preferred access: medially lying UPPER POLE calyx (lower poles face anteriorly → anterior vessels at risk)
• Lower pole and pelvis: anteriorly facing → risk of iliac artery injury
• Upper poles: usually well below ribs → safer supra/subcostal access
• CT guidance often helpful to plan

3. Transplant Kidney

• Location: iliac fossa (anterior, extraperitoneal, superficial)
• Approach: patient supine
• Preferred entry: lateral upper pole or interpolar anterior-facing calyx (allows access to PUJ and ureter for stenting)
• Advantages: very superficial → excellent US visualization
• Challenges:
  • Must avoid peritoneum (bowel injury if anterior puncture)
  • Capsular fibrosis → may need to overdilate tract by 2 French
  • No psoas muscle as landmark; anatomy reversed
  • Risk of puncturing inferior epigastric artery
• Overdilatation by 2F recommended to facilitate catheter passage through fibrotic capsule

4. Pregnancy

• Indication: urolithiasis not resolving conservatively
• Guidance: US-guided PCN (minimize fluoroscopy)
• Position: lateral or supine/oblique approach
• Analgesia: IV opiates (minimal risk); avoid fluoroscopy as much as possible
• When fluoroscopy needed: lead shielding of mother's abdomen, low-dose technique
• Never deny urgent PCN for pyonephrosis in pregnancy - maternal sepsis kills both mother and fetus

5. Paediatric PCN

• General anaesthesia mandatory (cannot cooperate with sedoanalgesia)
• Technique: US-guided, same Seldinger principles
• Collecting system decompresses rapidly after needle entry (compliant system under high pressure)
• Use stiff 0.035-inch wire and advance catheter without pre-dilatation if possible
• Sizes: 5-6 French pigtail (neonatal 5F specific catheters available)
• Minimize radiation: low-dose fluoroscopy, good collimation, image capture not live screening

---

CHAPTER 10: PCN vs. URETERIC STENT - A KEY COMPARISON

Q: When do you choose PCN over retrograde ureteric stenting (JJ stent)?

Respondents (urologists + radiologists) in surveys: favor antegrade approaches with pelvic malignancy; favor retrograde in uncomplicated benign disease or coagulopathy.

DJ Stent Side Effects (relevant exam topic):

• Dysuria and frequency: up to 50% of patients (stent irritates trigone)
• Stent reflux → loin pain on voiding, recurrent UTI
• Biofilm formation and encrustation (require exchange every 3-6 months)
• Stent migration (up or down)
• Forgotten stent → encrustation → stone → "stent calculus"

---

CHAPTER 11: COMPLICATIONS OF PCN

Q: What are the complications of PCN? Give accepted threshold rates.

Accepted Complication Thresholds (Table 85.3 - Grainger & Allison):

Detailed Complication Management:

1. Haematuria

• Minor hematuria (streaky): almost universal, self-limiting; resolves in 24-48h
• Frank hematuria with clots: may need bladder catheterization and washout
• Cause: Crossing arterial/venous vessels
• Management:
  • Venous bleeding: catheter tamponade (leave nephrostomy in situ, clamp if needed, gravity tamponade), transfusion if needed - usually resolves
  • Arterial bleeding: sustained → renal angiography + embolization
  • Angiography technique: first image with catheter in situ → if no bleeding point → withdraw catheter over guidewire (maintaining access) → repeat imaging to unmask occult bleeding point (pseudoaneurysm or AV fistula)
  • Last resort: nephrectomy

2. Sepsis / Bacteremia

• Most serious risk in pyonephrosis
• Prevention:
  • Prophylactic antibiotics before procedure
  • Do NOT inject contrast into infected/turbid collecting system (overdistension drives bacteria into bloodstream)
  • Drain pus quickly; do not manipulate excessively
  • Delay nephrostogram until patient has recovered from sepsis
• Management: blood cultures, broad-spectrum IV antibiotics, ICU if septic shock

3. Tube Displacement / Dislodgement

• Most common procedural problem in long-term PCN
• Prevention: meticulous securing with Roman sandal suture + drain-fix dressing
• Most tubes have self-retaining pigtail (string locked inside hub)
• If displaced:
  • Replace over guidewire under fluoroscopy within 24-72 hours (track remains patent for ~72h)
  • After 72h: track may close; may need re-puncture
• Removal under fluoroscopy: unlock pigtail first; never pull without unlocking

4. Bowel Injury (Rare - <1%)

• Retrorenal colon is the main risk (incidence <1%; higher in jejunoileal bypass/SCI patients)
• CT can identify retrorenal colon preoperatively
• If recognized during procedure:
  1. Withdraw guidewire out of kidney
  2. Leave drain in colon (acts as controlled colostomy)
  3. Perform separate second PCN for renal drainage
  4. After few days: nephrostogram to exclude renocolic fistula
  5. If no fistula → remove colonic catheter
  6. If peritonitis develops → surgical intervention
  7. Mature fistula track minimizes colonic spillage

5. Pleural Complications (Rare - 0.1-0.2%)

• Pneumothorax, hydrothorax, hemothorax, empyema
• Occur with supracostal access (above 12th rib)
• Prevention: access below 12th rib whenever possible
• Upper pole access (for stones): supra-12th rib access often unavoidable → accept pleural risk
• Treatment: chest drain if symptomatic pneumothorax or significant pleural effusion

6. Renal / Pelvic Injury

• Overzealous tract dilatation can rupture renal pelvis
• Take care with dilators towards renal pelvis and ureter
• Avoid kinked guidewires → dilator injury
• Most self-limiting; treat with prolonged internal or external drainage

---

CHAPTER 12: PCN AS ACCESS FOR PCNL

Q: When is PCN used as an access route for PCNL? What are the principles of planning PCNL access?

Indications for PCNL (through planned PCN access):

• Renal pelvic stones >2 cm
• Staghorn calculi (branched/complex stones)
• Lower pole stones >1 cm (SWL poor clearance due to dependent position)
• Stones in poorly draining kidneys (calyceal diverticulum, horseshoe kidney)
• Hard stones (CT density >1000 Hounsfield Units) - SWL ineffective
• Cystine stones (harder, SWL resistant)
• Less common: UTUC resection, endopyelotomy (PUJ obstruction), balloon dilatation, foreign body retrieval

Tract Planning Principles:

1. Posterior calyces allow access to anterior calyces (wire navigates around)
2. Anterior calyceal entry = poor intrarenal navigation
3. Upper pole entry:
   • Best for accessing PUJ and proximal ureter
   • Risk: puncture posterior division artery; may puncture pleura (above 12th rib)
4. Lower pole entry:
   • Best for pelvis and lower calyces
   • Some interpolar calyces may be difficult from lower pole access

PCNL Tract Sizes:

Note: Smaller sheaths = lower complication rate but longer operative time; general principles of access same for all sizes.

PCNL Access Step Summary:

1. Place retrograde ureteric catheter (allows contrast injection + defines PUJ)
2. Position prone or supine (Valdivia position for supine PCNL)
3. Opacify collecting system (retrograde contrast)
4. Target posterior calyx based on stone position and tract planning
5. Puncture under US ± fluoroscopy guidance
6. Pass stiff Amplatz wire - coil in pelvis OR advance to ureter
7. Dilate tract: serial Amplatz dilators OR one-shot balloon dilator (Amplatz balloon dilator)
8. Place Amplatz sheath (28-30F)
9. Insert nephroscope → fragmentation (ultrasonic, pneumatic, laser) → extraction
10. Leave PCN tube at end OR "tubeless PCNL" (if complete stone clearance, no bleeding, no collecting system injury)

---

CHAPTER 13: CATHETER CARE AND REMOVAL

Q: How do you manage a PCN tube after insertion? When do you remove it?

Post-PCN Care:

• Monitor: urine output, drain color, vital signs
• 24h urine output monitoring - check for post-obstructive diuresis (see below)
• Secure tube: Roman sandal suture + drain-fix dressing; check fixation every shift
• Flush the tube: some protocols flush with 5-10 mL normal saline every 8 hours (prevents blockage)
• Nephrostogram (contrast through PCN tube): performed when patient recovered from acute sepsis; assesses anatomy, residual obstruction, flow to bladder

Post-Obstructive Diuresis:

• After relieving chronic bilateral obstruction or obstruction of solitary kidney
• Physiological: excess Na, water, urea excreted (appropriate)
• Pathological: loss of concentrating ability, continued massive diuresis >200 mL/hr
• Management:
  • Monitor urine output hourly
  • Replace 50-75% of urine output as IV fluid
  • Monitor Na, K, creatinine every 4-6h
  • Usually self-limiting; watch for hyponatremia, hypokalemia, dehydration

PCN Tube Exchange:

• Tubes typically require exchange every 4-6 weeks (sooner if encrusted or blocked)
• Exchange over guidewire under fluoroscopy
• Always use guidewire for exchange - never just pull and push

Removal of PCN:

• Performed under fluoroscopy using guidewire
• Technique:
  1. Unlock the pigtail string first (hub of catheter)
  2. Pass guidewire down the tube
  3. Withdraw tube over wire
  4. If pigtail cannot be unlocked → cut tube at hub (risk of suture fragment retention)
  5. Retained suture can be caught in soft tissue on withdrawal - retrieve fragment

When to Remove PCN:

• Obstruction definitively relieved (stent placed, stone passed, stricture dilated)
• Performing clamp test before removal in some centers:
  • Clamp PCN for 24-48h
  • If patient comfortable, urine draining per urethra, no fever → safe to remove
  • If pain, fever, anuria → unclamp; obstruction not yet relieved

---

CHAPTER 14: PCN IN SPECIFIC CLINICAL SCENARIOS

Q: Examiner walks you through clinical scenarios - answer each one.

---

• IV antibiotics IMMEDIATELY (broad-spectrum - tazocin/pip-taz or meropenem)
• Blood cultures before antibiotics
• Urgent PCN - do NOT delay for stone treatment
• Resuscitate: fluids, monitor urine output, HDU admission
• Stone treatment DEFERRED until infection controlled (minimum 4-6 weeks)
• Never try to stent through an obstructed infected kidney in a systemically unwell patient (risk of septic shower)

---

• Bilateral PCN (may do sequentially same session or 24-48h apart)
• Monitor renal function recovery
• Counsel patient: PCN may improve quality of life but prognosis determined by underlying malignancy
• Discuss with oncology - if chemotherapy/radiotherapy planned, PCN enables treatment
• Can later be converted to bilateral DJ stents (internal) if appropriate

---

• PCN for decompression
• OR retrograde DJ stent if accessible
• If ureteric perforation → PCN preferred (diverts urine, reduces extravasation)

---

• Do NOT inject contrast (risk of bacteremia/endotoxemia from overdistension)
• Send aspirate for urgent culture and sensitivity
• Proceed directly to wire placement and tube insertion
• Use small caliber catheter (8-10F sufficient for initial drainage)
• Continue IV antibiotics
• Patient may still develop septic shock even after drainage - monitor closely in HDU
• Once patient stable, perform nephrostogram to plan definitive management

---

• Stop PCNL if possible; leave Amplatz sheath in place to tamponade parenchymal bleeding
• Insert chest drain if pneumothorax/hemothorax is significant
• Small pleural effusion: may resolve with observation
• Prevention: avoid puncture above 12th rib; plan lower pole access when possible for pelvic/lower stones

---

CHAPTER 15: HIGH-YIELD FACTS & MNEMONICS

Must-Know Facts Table:

---

MNEMONICS:

• Obstruction
• Urosepsis / Urine diversion
• Pyonephrosis
• Access for procedures (PCNL, stenting, endopyelotomy)
• Urinary fistula/leak
• Functional tests (Whitaker test)

• Consent
• Access (IV, fluids)
• Bloods (FBC, coag, U&E)
• Imaging review
• Infection (cultures + prophylactic antibiotics)
• Anaesthesia (sedoanalgesia or GA)

• Sepsis
• Bleeding (hematuria, hemorrhage)
• Pleural complications
• Bowel injury
• Renal/pelvic injury; tube Removal problems

---

CHAPTER 16: EXAMINER TRAPS

1. "I'll give contrast injection first to confirm calyx position in a patient with pyonephrosis"

WRONG. Do NOT inject contrast or manipulate an infected collecting system more than necessary. Overdistension drives bacteria into the venous sinuses → bacteremia → septic shock. Aspirate pus, confirm position by aspiration of fluid, advance wire directly.

2. "There's no urgency in PCN - we'll do it in the morning"

WRONG for pyonephrosis. These patients can deteriorate to septic shock within hours. Delay of even a few hours is life-threatening. PCN must be done immediately, even out-of-hours, for infected obstruction.

3. "I'll puncture the anterior calyx for easier access"

WRONG. Anterior calyceal entry → crosses anterior segmental vessels → risk of major hemorrhage. These vessels cannot be tamponaded by nephrostomy tube. Always target posterior calyx.

4. "The coagulopathy is so bad I can't do PCN"

WRONG (in life-threatening pyonephrosis). Correct coagulopathy simultaneously and proceed. No absolute contraindication. The risk of NOT doing PCN exceeds the bleeding risk when the patient is dying from sepsis.

5. "I'll remove the PCN tube by just pulling it out"

WRONG. Always unlock the pigtail first (pull string at hub), then remove over guidewire under fluoroscopy. Pulling a locked pigtail tears collecting system.

6. "Upper pole access is best avoided for all cases"

WRONG. Upper pole posterior calyx access is needed for:

• Staghorn stones needing access to PUJ
• Proximal ureteral calculi
• Endopyelotomy Yes, it carries higher pleural risk, but it is essential for certain stone configurations.

7. "PCN and ureteric stent are equal in all situations - just pick one"

Not quite. PCN is preferred in pelvic malignancy (edematous ureteric orifice makes retrograde access difficult). Retrograde stent preferred in uncomplicated benign distal stone. Clinical context determines choice.

---

CHAPTER 17: CLINICAL VIGNETTES

• Septic shock from obstructed infected right kidney
• Resuscitate: IV fluids, vasopressors if needed
• Blood cultures, urine culture
• IV antibiotics immediately (piperacillin-tazobactam or meropenem)
• Urgent bedside ultrasound-guided PCN right kidney - cannot wait until morning
• Aspiration of pus confirms pyonephrosis → drain; do NOT inject contrast
• HDU admission; stone treatment after 4-6 weeks when fully recovered

• Hydrothorax from supracostal upper pole PCNL access
• Stop PCNL temporarily; maintain Amplatz sheath access
• Chest drain for symptomatic hydrothorax
• Complete PCNL if patient stable (may need to continue same sitting or second sitting)
• Post-op CXR mandatory

• Tube displacement / kinking is likely
• Check: is tube draining? Is pigtail still inside (check on fluoroscopy)?
• If tube blocked: flush with saline; if fails, change tube over guidewire under fluoroscopy
• If tube fine: consider post-obstructive diuresis resolving (normal)
• If no output and fever: check tube position urgently

• Clamp test first: clamp PCN for 24-48h; monitor pain, fever, urine output
• If patient tolerates clamping → safe to remove
• Remove under fluoroscopy: unlock pigtail string, remove over guidewire, apply dressing
• If patient develops pain/fever on clamping → unclamp; permanent PCN or convert to internal stent

---

---